SCHEMBL3328067

SCHEMBL3328067

COc1ccc(B(O)O)c(OC)c1O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 5/20 0.49
TUBB P07437 5/20 0.49
TUBA3C P0DPH7 5/20 0.49
TUBA1B P68363 5/20 0.49
TUBA4A P68366 5/20 0.49
TUBB4B P68371 5/20 0.49
TUBB3 Q13509 5/20 0.49
TUBB2A Q13885 5/20 0.49
TUBB8 Q3ZCM7 5/20 0.49
TUBA3E Q6PEY2 5/20 0.49
TUBA1A Q71U36 5/20 0.49
TUBA1C Q9BQE3 5/20 0.49
TUBB6 Q9BUF5 5/20 0.49
TUBB2B Q9BVA1 5/20 0.49
TUBB1 Q9H4B7 5/20 0.49
ENPP2 Q13822 1/20 0.47
MAPT P10636 3/20 0.43
CYP3A4 P08684 2/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29466487 0.83 TUBB4A (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL23439 0.83 TUBB4A (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1402474 0.80 MAPT (0.61) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL6828096 0.79 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30364533 0.78 MAPT (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12584714 0.78 MAPT (0.46) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL6828237 0.78 TUBB4A (0.47) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL5349727 0.76 CYP3A4 (0.54) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3687594 0.75 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL1796152 0.75 TUBB4A (0.49) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100130473-A1 COMPOUNDS HUMMERSONE MARC GEOFFREY 2010-05-27 US disclosed
US-7504397-B2 mTOR inhibitor compounds KUDOS PHARMACEUTICALS LTD. (GB) 2009-03-17 US disclosed
EP-1877388-A2 HYDRAZINOMETHYL, HYDRAZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS Kudos Pharmaceuticals Ltd (GB) 2008-01-16 EP disclosed
US-20060199804-A1 Compounds KUDOS PHARMACEUTICALS LTD (GB) 2006-09-07 US disclosed
WO-2006090167-A2 HYDRAZINOMETHYL, HYDR ZONOMETHYL AND 5-MEMBERED HETEROCYLIC COMPOUNDS WHICH ACT AS MTOR INHIBITORS AND THEIR USE AS ANTI CANCER AGENTS KUDOS PHARMACEUTICALS LIMITED (GB) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060199804-A1 Compounds CA4, CA6, CYP2B6 TUBB4A 2423/4885TUBB 3535/4885TUBA3C 3308/4885
US-20100130473-A1 COMPOUNDS CA6, CYP2B6, CA4 TUBB4A 2199/4885TUBB 3326/4885TUBA3C 2793/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.